Silvy da Rocha Dias

Oncogenic Braf Induces Melanocyte Senescence and Melanoma in Mice

Nathalie Dhomen, Jorge S. Reis‐Filho, Silvy da Rocha Dias et al. · Cancer Cell · 2009 · 571 citations · Full text

Melanoma, Cellular Senescence, Medicine +3

Activated B-RAF Is an Hsp90 Client Protein That Is Targeted by the Anticancer Drug 17-Allylamino-17-Demethoxygeldanamycin

Silvy da Rocha Dias, Frank Friedlos, Yvonne Light et al. · Cancer Research · 2005 · 243 citations

CTLA-4 up-regulation of lymphocyte function-associated antigen 1 adhesion and clustering as an alternate basis for coreceptor function

Helga Schneider, Elke Valk, Silvy da Rocha Dias et al. · Proceedings of the National Academy of Sciences · 2005 · 121 citations · Full text

Lymphocyte Development, T-regulatory Cell, Immunology +20

The European Medicines Agency review of vemurafenib (Zelboraf®) for the treatment of adult patients with BRAF V600 mutation-positive unresectable or metastatic melanoma: Summary of the scientific assessment of the Committee for Medicinal Products for Human Use

Silvy da Rocha Dias, Tomas Salmonson, Barbara van Zwieten‐Boot et al. · European Journal of Cancer · 2013 · 54 citations

Preclinical Therapeutics, Medicine, Melanoma +9

A regulatory role for cytoplasmic YVKM motif in CTLA-4 inhibition of TCR signaling

Helga Schneider, Silvy da Rocha Dias, Hui Hu et al. · European Journal of Immunology · 2001 · 37 citations · Full text